Oncología médica

2019

1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

   Frontiers in Oncology, Vol. 9, Núm. APR

2. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

   Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

3. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

   Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

4. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

   Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

5. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

   European Journal of Surgical Oncology, Vol. 45, Núm. 10, pp. 1876-1881

6. Cohort profile: Design and methods of the PREDIMED-Plus randomized trial

   International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o

7. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

   Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701

8. Germline c.1A>C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): A case report

   Hereditary Cancer in Clinical Practice, Vol. 17, Núm. 1

9. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors

   Reumatologia Clinica, Vol. 15, Núm. 4, pp. 211-217

10. Liquid biopsy in glioblastoma: Opportunities, applications and challenges

    Cancers, Vol. 11, Núm. 7

11. Malar bone metastasis of oncocytic neuroendocrine tumour of the lung

    Revista Espanola de Cirugia Oral y Maxilofacial, Vol. 41, Núm. 3, pp. 145-148

12. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

13. Metástasis en hueso malar de tumor neuroendocrino oncocítico pulmonar

    Revista española de cirugía oral y maxilofacial: Publicación Oficial de la Sociedad Española de Cirugía Oral y Maxilofacial, Vol. 41, Núm. 3, pp. 145-148

14. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer

    Thrombosis and Haemostasis, Vol. 119, Núm. 11, pp. 1849-1859

15. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

16. Omics approaches in pancreatic adenocarcinoma

    Cancers, Vol. 11, Núm. 8

17. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

18. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 64-74

19. SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 31-45

20. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789